Glycosmedia Weekly Diabetes News - 08/06/2021

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study

Combined eplerenone and ACEi therapy increases Ang-(1–7) levels in patients with CKD indicating a unique nephroprotective RAAS pattern with considerable therapeutic implications (Diabetes Therapy)

Effects of intermittent very-low calorie diet on glycemic control and cardiovascular risk factors in obese patients with type 2 diabetes mellitus: A randomized controlled trial

Intermittent VLCD was highly effective in achieving optimal glycemic control. The effects of 2 days/week and 4 days/week of intermittent VLCD on diabetes remission were relatively similar (Journal of Diabetes Investigation)

A New Clinical Utility For Tubular Markers To Identify Kidney Responders To Saxagliptin Treatment In Patients With Diabetic Nephropathy

The albuminuria-lowering effect of saxagliptin may be due to inhibition of kidney tubular damage. The use of tubular markers may be regarded as a promising tool to identify kidney responders to gliptins (Canadian Journal of Diabetes)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

The initiation of SGLT-2i as compared with other glucose-lowering drugs in routine clinical practice is associated with decreased risk of heart failure, all-cause death, myocardial infarction and stroke (Cardiovascular Diabetology)

Effect of Long-Term Proton Pump Inhibitor Use on Glycemic Control in Patients with Type Two Diabetes Mellitus

Those on PPI had an increase in HbA1c of 0.16 compared to 0.08 in those not prescribed PPI. Our results show no relationship between the length of PPI therapy and HbA1c reduction (Journal of Diabetes Research)